Wnt/β-catenin信号通路在骨肉瘤与骨重建及血管生成中的多重话题

doi:10.3969/j.issn.2095-4344.2871

中国组织工程研究 ›› 2020, Vol. 24 ›› Issue (32): 5213-5220.doi: 10.3969/j.issn.2095-4344.2871

• 组织构建综述 tissue construction review • 上一篇下一篇

Wnt/β-catenin信号通路在骨肉瘤与骨重建及血管生成中的多重话题

刘畅，宋科官

哈尔滨医科大学附属第一医院，黑龙江省哈尔滨市 150001

收稿日期:2020-01-07 修回日期:2020-01-10 接受日期:2020-03-04 出版日期:2020-11-18 发布日期:2020-09-26
通讯作者: 宋科官，主任医师，教授，哈尔滨医科大学附属第一医院骨三科，黑龙江省哈尔滨市 150001
作者简介:刘畅，男，1989年生，黑龙江省方正县人，汉族，2020年哈尔滨医科大学毕业，硕士，医师，主要从事关节外科研究。
基金资助:
国家重点研发计划(2017YFB0702600；2017YFB0702604)

Wnt/beta-catenin signaling pathway: multiple roles in osteosarcoma, bone remodeling and angiogenesis

Liu Chang, Song Keguan

First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China

Received:2020-01-07 Revised:2020-01-10 Accepted:2020-03-04 Online:2020-11-18 Published:2020-09-26
Contact: Song Keguan, Chief physician, Professor, First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China
About author:Liu Chang, Master, Physician, First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China
Supported by:
the National Key Research and Development Program of China, No. 2017YFB0702600; 2017YFB0702604

摘要/Abstract

摘要：

文题释义：

肿瘤微环境：是指肿瘤的发生、生长及转移与肿瘤细胞所处的内外环境有着密切关系，它不仅包括肿瘤所在组织的结构、功能和代谢，而且亦与肿瘤细胞自身的(核和胞质)内在环境有关。肿瘤细胞可以通过自分泌和旁分泌，改变和维持自身生存和发展的条件，促进肿瘤的生长和发展。

上皮间质转化：指上皮到间质细胞的转化，它赋予细胞转移和入侵的能力，包括干细胞特征、减少凋亡与衰老，和促进免疫抑制，不仅在发育过程中起着关键的作用，而且还参与组织愈合、器官纤维化和癌症发生等过程。

背景：Wnt/β-catenin信号通路在骨肉瘤的肿瘤发生和骨重建中起的关键作用，及其在血管生成和免疫监视中的意义，是转移性播散的2个关键机制。

目的：文章就Wnt/β-catenin通路在骨肉瘤发生发展中的作用及其对特定微环境的调控进行综述。

方法：检索2000年至2020年为止的PubMed数据库，以“Wnt/β-catenin；bone tumors”为英文检索词，得到Wnt/β-catenin通路与骨肿瘤关系的相关研究。

结果与结论：典型的Wnt/β-catenin信号通路通过直接作用于骨肉瘤细胞和间接调节骨肉瘤细胞活性2种方式在骨肉瘤生长和转移过程中起着重要作用。Wnt/β-catenin通路也参与了骨肉瘤细胞对骨肿瘤微环境的劫持，促进细胞外基质的调节，使肿瘤细胞具有侵袭性，诱导肿瘤细胞的免疫耐受和血管生成，最终导致转移扩散的增加。另外，骨肉瘤细胞中典型Wnt信号通路的异常激活似乎与细胞增殖、上皮间质转化样过程的诱导、骨肉瘤促肿瘤细胞干细胞特性的获得以及转移扩散密切相关。

ORCID: 0000-0003-0353-4895(刘畅)

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

关键词: Wnt/β-catenin, 骨肉瘤, 骨肿瘤微环境, 治疗策略, 通路, 综述

Abstract:

BACKGROUND: The Wnt/β-catenin signaling pathway plays a key role in osteosarcoma tumorigenesis and bone remodeling, and its roles in angiogenesis and immune surveillance are the two key mechanisms of metastatic dissemination.

OBJECTIVE: To review the role of Wnt/β-catenin pathway in the occurrence and development of osteosarcoma and its regulatory role in specific microenvironment.

METHODS: PubMed database was searched for relevant articles on the relationship between Wnt/β-catenin pathway and bone tumors using the search terms of “Wnt/β-catenin; bone tumors.” The search time for publications was from 2000 to 2020.

RESULTS AND CONCLUSION: The typical Wnt/β-catenin signaling pathway plays an important role in the growth and metastasis of osteosarcoma by directly acting on osteosarcoma cells and indirectly regulating cell activity in osteosarcoma. The Wnt/β-catenin pathway also participates in the hijacking of the bone tumor microenvironment by osteosarcoma cells, promotes the regulation of extracellular matrix, makes the tumor cells invasive, induces immune tolerance and angiogenesis in tumor cells, and eventually augments metastatic spread. In addition, the typical Wnt signaling pathway abnormally activated in osteosarcoma cells seems to be closely related to cell proliferation, induction of epithelial-mesenchymal transition-like processes, acquisition of osteosarcoma-promoting tumor cell stem cell characteristics, and metastatic spread.

Key words: Wnt/β-catenin, osteosarcoma, bone tumor microenvironment, treatment strategy, pathway, review

中图分类号:

刘畅, 宋科官. Wnt/β-catenin信号通路在骨肉瘤与骨重建及血管生成中的多重话题[J]. 中国组织工程研究, 2020, 24(32): 5213-5220.

Liu Chang, Song Keguan. Wnt/beta-catenin signaling pathway: multiple roles in osteosarcoma, bone remodeling and angiogenesis[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(32): 5213-5220.

图/表（结果） 2

参考文献

[1] STRAUSS SJ, WHELAN JS. Current questions in bone sarcomas. Curr Opin Oncol.2018;30:252-259.

[2] LU P, WEAVER VM, WERB Z. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol.2012; 196:395-406.

[3] CRENN V, BITEAU K, AMIAUD J, et al.Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: Retrospective analysis and preclinical modeling. Am J Cancer Res.2017;7:2333-2349.

[4] ALFRANCA A, MARTINEZ-CRUZADO L, TORNIN J, et al.Bone microenvironment signals in osteosarcoma development.Cell Mol Life Sci.2015;72:3097-3113.

[5] JIN H, BARROTT JJ, CABLE MG, et al. The Impact of Microenvironment on the Synovial Sarcoma Transcriptome.Cancer Microenviron.2017;10:1-7.

[6] GOLDSTEIN SD, HAYASHI M, ALBERT CM, et al. An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis.Clin Exp Metastasis.2015;32:703-715.

[7] RIEMANN A, SCHNEIDER B, GÜNDEL D, et al .Acidosis Promotes Metastasis Formation by Enhancing Tumor Cell Motility. Adv Exp Med Biol.2016;876:215-220.

[8] CHATTOPADHYAY S, CHAKLADER M, CHATTERJEE R,et al. Differential expression of mitotic regulators and tumor microenvironment influences the regional growth pattern of solid sarcoma along the cranio-caudal axis.Exp Cell Res. 2016;340:91-101.

[9] LAMOUREUX F, RICHARD P, WITTRANT Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res.2007;67:7308-7318.

[10] DASS CR, CHOONG PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model.Mol Cancer Ther.2007;6: 3263-3270.

[11] HAN Y, WU C, WANG J, et al. CXCR7 maintains osteosarcoma invasion after CXCR4 suppression in bone marrow microenvironment. Tumour Biol. 2017;39:101042831770163.

[12] CORTINI M, MASSA A, AVNET S, et al. Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion.PLoS ONE.2016;11: e0166500.

[13] QI J, ZHOU Y, JIAO Z, et al. Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Promote Tumor Growth Through Hedgehog Signaling Pathway.Cell Physiol Biochem. 2017;42:2242-2254.

[14] WANG Y, CHU Y, YUE B, et al. Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway.Oncotarget.2017;8:23803-23816.

[15] HEYMANN MF, LÉZOT F, HEYMANN D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma.Cell Immunol. 2019;343:103711.

[16] NOY R, POLLARD JW.Tumor-associated macrophages: From mechanisms to therapy.Immunity.2014;41:49-61.

[17] GOMEZ-BROUCHET A, ILLAC C, GILHODES J, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.Oncoimmunology.2017;6:e1331193.

[18] DUMARS C, NGYUEN JM, GAULTIER A, et al.Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.Oncotarget.2016;7:78343-78354.

[19] ZHOU Q, XIAN M, XIANG S, et al.All Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor- Associated Macrophages.Cancer Immunol Res.2017;5:547-559.

[20] HAN Q, SHI H, LIU F. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol. 2016;34:101-106.

[21] CHANG CH, QIU J, O’SULLIVAN D, et al.Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell.2015;162:1229-1241.

[22] LEWIS DM, PRUITT H, JAIN N, et al.A Feedback Loop between Hypoxia and Matrix Stress Relaxation Increases Oxygen-Axis Migration and Metastasis in Sarcoma.Cancer Res. 2019;79: 1981-1995.

[23] ITOH H, KADOMATSU T, TANOUE H, et al. TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.Oncogene. 2018;37: 2903-2920.

[24] PIPERNO-NEUMANN S, LE DELEY MC, RÉDINI F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): A randomised, multicentre, open-label, phase 3 trial.Lancet Oncol.2016;17:1070-1080.

[25] DUCHARTRE Y, KIM YM, KAHN M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol.2016;99: 141-149.

[26] ZHAN T, RINDTORFF N, BOUTROS M. Wnt signaling in cancer. Oncogene.2017;36:1461-1473.

[27] HARB J, LIN PJ, HAO J. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics. Curr Oncol Rep. 2019;21:12.

[28] KAHN M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513-532.

[29] CHEN C, ZHAO M, TIAN A, et al.Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells.Oncotarget. 2015;6:17570-17583.

[30] LU Y, GUAN GF, CHEN J,e t al.Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival.Oncol Lett.2015;10:2123–2129.

[31] CAI Y, MOHSENY AB, KARPERIEN M, et al. Inactive Wnt/beta- catenin pathway in conventional high-grade osteosarcoma.J Pathol. 2010;220:24-33.

[32] SHIMOZAKI S,YAMAMOTO N, DOMOTO T, et al. Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin.Oncotarget.2016;7:77038-77051.

[33] JIE XX, ZHANG XY, XU CJ. Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications. Oncotarget 2017;8:81558-81571.

[34] YANG G, YUAN J, LI K. EMT transcription factors: Implication in osteosarcoma.Med Oncol.2013;30: 697.

[35] VERRECCHIA F, RÉDINI F. Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment.Front Oncol. 2018;8:133.

[36] FUXE J, VINCENT T, DE GARCIA HERREROS A. Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363-2374.

[37] TIAN H, ZHOU T, CHEN H, et al. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.J Orthop Res.2019;37: 1638-1648.

[38] WANG S, ZHANG D, HAN S, et al.Fibulin-3 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition and activating the Wnt/β-catenin signaling pathway.Sci Rep.2017; 7:6215.

[39] FAN S, GAO X, CHEN P, et al. Carboxypeptidase E-ΔN promotes migration, invasiveness, and epithelial mesenchymal transition of human osteosarcoma cells via the Wnt-β-catenin pathway. Biochem. Cell Biol.2018:1-8.

[40] ZENG Q, LI Z, ZHAO X, et al. Ubiquitin-specific protease 7 promotes osteosarcoma cell metastasis by inducing epithelial-mesenchymal transition. Oncol Rep.2019;41:543-551.

[41] CAI Z, CAO Y, LUO Y, et al. Signalling mechanism(s) of epithelial-mesenchymal transition and cancer stem cells in tumour therapeutic resistance.Clin Chim Acta.2018;483:156-163.

[42] TAKEBE N, MIELE L, HARRIS PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol.2015;12:445-464.

[43] ADHIKARI AS, AGARWAL N, WOOD BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.Cancer Res. 2010;70:4602-4612.

[44] MARTINS-NEVES SR, CORVER WE, PAIVA-OLIVEIRA DI, et al. Osteosarcoma Stem Cells Have Active Wnt/β- catenin and Overexpress SOX2 and KLF4.J Cell Physiol.2016;231:876-886.

[45] LIU Y, WANG Y, YANG H, et al. MicroRNA-873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β-catenin pathway.Int J Oncol.2019;54:1809-1820.

[46] CAI W, XU Y, YIN J, et al. miR-552-5p facilitates osteosarcoma cell proliferation and metastasis by targeting WIF1. Exp Ther Med.2019;17:3781-3788.

[47] LIU Y, BAO Z, TIAN W, et al. miR-885-5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β-catenin.Oncol Lett.2019;17:1996-2004.

[48] REN J, YANG M, XU F, et al.microRNA-758 inhibits the malignant phenotype of osteosarcoma cells by directly targeting HMGA1 and deactivating the Wnt/β-catenin pathway.Am J Cancer Res. 2019;9: 36-52.

[49] XIA P, GU R, ZHANG W, et al.MicroRNA-377 exerts a potent suppressive role in osteosarcoma through the involvement of the histone acetyltransferase 1-mediated Wnt axis.J Cell Physiol. 2019;234(12):22787-22798.

[50] LI C, WANG F, WEI B, et al. LncRNA AWPPH promotes osteosarcoma progression via activation of Wnt/β-catenin pathway through modulating miR-93-3p/FZD7 axis. Biochem. Biophys. Res Commun.2019;514: 1017-1022.

[51] BROWN HK, SCHIAVONE K, GOUIN F, et al.Biology of Bone Sarcomas and New Therapeutic Developments. Calcif Tissue Int. 2018;102:174-195.

[52] PEDERSON L, RUAN M, WESTENDORF JJ, et al.Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci.USA 2008;105: 20764-20769.

[53] WEIVODA MM, RUAN M, HACHFELD CM, et al.Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways.J Bone Miner Res.2016; 31:65-75.

[54] SADANANDAM A, FUTAKUCHI M, LYSSIOTIS CA, et al.A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling. BMC Cancer.2011; 11:304.

[55] BU G, LU W,LIU CC, et al.Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases.Int J Cancer.2008; 123:1034-1042.

[56] BJØRNLAND K, FLATMARK K, PETTERSEN S,et al.Matrix metalloproteinases participate in osteosarcoma invasion.J Surg Res.2005;127:151-156.

[57] KUNZ P, SÄHR H, LEHNER B, et al. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma.BMC Cancer.2016;16:223.

[58] GUO Y, ZI X, KOONTZ Z, et al.Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells.J Orthop Res.2007;25:964-971.

[59] LIU B, LI G, WANG X, et al.A furin inhibitor downregulates osteosarcoma cell migration by downregulating the expression levels of MT1-MMP via the Wnt signaling pathway.Oncol Lett. 2014;7: 1033-1038.

[60] OLSEN JJ, POHL SÖ, DESHMUKH A, et al.The Role of Wnt Signalling in Angiogenesis. Clin Biochem Rev. 2017;38;131-142.

[61] CARMELIET P, JAIN RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.Nat Rev Drug Discov.2011;10:417-427.

[62] MAVROGENIS AF, VOTTIS CT, MEGALOIKONOMOS PD, et al. Neovascularization in Ewing’s sarcoma. Neoplasma.2018;65: 317-325.

[63] CHEN D, ZHANG YJ, ZHU K, et al. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.Tumour Biol.2013;34: 1895-1899.

[64] YANG J, YANG D, SUN Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA,in human osteosarcoma.Cancer.2011;117: 4925-4938.

[65] EASWARAN V, LEE SH, INGE L, et al.beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res.2003;63:3145-3153.

[66] KAWANO Y, KYPTA R. Secreted antagonists of the Wnt signalling pathway.J Cell Sci.2003;116: 2627-2634.

[67] DUFOURCQ P, LEROUX L, EZAN J, et al. Regulation of endothelial cell cytoskeletal reorganization by a secreted frizzled- related protein-1 and frizzled 4- and frizzled 7-dependent pathway: Role in neovessel formation.Am J Pathol.2008;172:37-49.

[68] MULEY A, MAJUMDER S, KOLLURU GK, et al. Secreted frizzled-related protein 4: An angiogenesis inhibitor. Am J Pathol. 2010;176:1505-1516.

[69] ZHAO S, KURENBEKOVA L, GAO Y, et al.NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma.Oncogene.2015;34:5069.

[70] LIAO D, JOHNSON RS. Hypoxia: A key regulator of angiogenesis in cancer.Cancer Metastasis Rev. 2007; 26;281-290.

[71] KROCK BL, SKULI N, SIMON MC. Hypoxia-induced angiogenesis: Good and evil.Genes Cancer.2011;2: 1117-1133.

[72] ZHANG XD, WU Q, YANG SH.Effects of siRNA-mediated HIF-1α gene silencing on angiogenesis in osteosarcoma. Pak J Med Sci. 2017;33:341-346.

[73] ZHANG B, LI YL, ZHAO JL, et al.Hypoxia-inducible factor-1 promotes cancer progression through activating AKT/Cyclin D1 signaling pathway in osteosarcoma. Biomed Pharmacother.2018; 105:1-9.

[74] LI Y, ZHANG W, LI S, et al. Prognosis value of Hypoxia-inducible factor-1α expression in patients with bone and soft tissue sarcoma: A meta-analysis.Springerplus.2016;5:1370.

[75] DEMIR R, DIMMLER A, NASCHBERGER E, et al. Malignant progression of invasive tumour cells seen in hypoxia present an accumulation of beta-catenin in the nucleus at the tumour front. Exp Mol Pathol. 2009;87:109-116.

[76] KAIDI A, WILLIAMS AC, PARASKEVA C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol.2007;9:210-217.

[77] SCHOLTEN DJ 2ND, TIMMER CM, PEACOCK JD, et al.Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.PLoS ONE. 2014; 9:e111431.

[78] QIAN BZ, POLLARD JW. Macrophage diversity enhances tumor progression and metastasis.Cell.2010; 141:39-51.

[79] YANG Y, YE YC, CHEN Y, et al.Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors.Cell Death Dis.2018;9:793.

[80] LIU T, FANG XC, DING Z, et al.Pre-operative lymphocyte-to- monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma. FEBS Open Bio.2015;5:682-687.

[81] ASSAL A, KANER J, PENDURTI G, et al.Emerging targets in cancer immunotherapy: Beyond CTLA-4 and PD-1. Immunotherapy. 2015;7:1169-1186.

[82] KOIRALA P, ROTH ME, GILL J, et al. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival.Sci Rep.2016;6:31154.

[83] KOIRALA P, ROTH ME, GILL J, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.Sci Rep.2016;6:30093.

[84] WANG L, ZHANG Q, CHEN W, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.PLoS ONE.2013;8:e70689.

[85] LUKE JJ, BAO R, SWEIS RF, et al. Wnt/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res.2019;25:3074-3083.

[86] SPRANGER S, BAO R, GAJEWSKI TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.Nature. 2015; 523:231-235.

[87] DE RUIZ GALARRETA M, BRESNAHAN E, MOLINA-SANCHEZ P, et al.β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124-1141.

[88] DHUPKAR P, GORDON N, STEWART J, et al.Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.Cancer Med.2018;7: 2654-2664.

[89] GALLUZZI L, SPRANGER S, FUCHS E, et al.WNT Signaling in Cancer Immunosurveillance.Trends Cell Biol. 2019;29:44-65.

Wnt/β-catenin信号通路在骨肉瘤与骨重建及血管生成中的多重话题

Wnt/beta-catenin signaling pathway: multiple roles in osteosarcoma, bone remodeling and angiogenesis

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表（结果） 2

参考文献

相关文章 15

引言

材料方法

讨论

文章快阅

延伸阅读

编辑推荐

Metrics

本文评价

[1]	蒲锐, 陈子扬, 袁凌燕. 不同细胞来源外泌体保护心脏的特点与效应[J]. 中国组织工程研究, 2021, 25(在线): 1-.
[2]	袁家威, 张海涛, 揭珂, 曹厚然, 曾意荣. 基于网络药理学研究桃红四物汤治疗假体周围感染的潜在靶点和机制[J]. 中国组织工程研究, 2021, 25(9): 1428-1433.
[3]	张超, 吕欣. 髋臼骨折固定后的异位骨化：危险因素、预防及其治疗进展[J]. 中国组织工程研究, 2021, 25(9): 1434-1439.
[4]	周继辉, 李新志, 周游, 黄卫, 陈文瑶. 髌骨骨折修复内植物选择的多重问题[J]. 中国组织工程研究, 2021, 25(9): 1440-1445.
[5]	王德斌, 毕郑刚. 尺骨鹰嘴骨折-脱位解剖力学、损伤特点、固定修复及3D技术应用的相关问题[J]. 中国组织工程研究, 2021, 25(9): 1446-1451.
[6]	顾霞, 赵敏, 王平义, 李一梅, 李文华. 低氧诱导因子1α与低氧相关疾病信号通路的关系[J]. 中国组织工程研究, 2021, 25(8): 1284-1289.
[7]	姬志祥, 蓝常贡. 尿酸盐转运蛋白在痛风中的多态性和治疗相关性[J]. 中国组织工程研究, 2021, 25(8): 1290-1298.
[8]	袁美, 张新新, 郭祎莎, 毕霞. 循环microRNA在血管性认知障碍诊断中的应用[J]. 中国组织工程研究, 2021, 25(8): 1299-1304.
[9]	柴乐, 吕建兰, 胡劲涛, 胡华辉, 许庆军, 余进伟, 全仁夫. 诱导急性脊髓损伤模型大鼠炎症反应信号通路的变化[J]. 中国组织工程研究, 2021, 25(8): 1218-1223.
[10]	李中峰, 陈明海, 凡一诺, 魏秋实, 何伟, 陈镇秋. 右归饮治疗激素性股骨头坏死作用机制的网络药理学分析[J]. 中国组织工程研究, 2021, 25(8): 1256-1263.
[11]	汪显耀, 关亚琳, 刘忠山. 提高间充质干细胞治疗难愈性创面的策略[J]. 中国组织工程研究, 2021, 25(7): 1081-1087.
[12]	万然, 史旭, 刘京松, 王岩松. 间充质干细胞分泌组治疗脊髓损伤的研究进展[J]. 中国组织工程研究, 2021, 25(7): 1088-1095.
[13]	廖成成, 安家兴, 谭张雪, 王倩, 刘建国. 口腔鳞状细胞癌干细胞的治疗靶点及应用前景[J]. 中国组织工程研究, 2021, 25(7): 1096-1103.
[14]	赵敏, 冯柳祥, 陈垚, 顾霞, 王平义, 李一梅, 李文华. 低氧环境下外泌体可作为疾病的标志物[J]. 中国组织工程研究, 2021, 25(7): 1104-1108.
[15]	谢文佳, 夏天娇, 周卿云, 刘羽佳, 顾小萍. 小胶质细胞介导神经元损伤在神经退行性疾病中的作用[J]. 中国组织工程研究, 2021, 25(7): 1109-1115.